Summary
A bioRxiv preprint reports that the RAF inhibitor ELV-3111, combined with a MEK inhibitor, suppressed MAPK signalling and produced tumour regressions in RAS- and BRAF-mutant models. The findings describe preclinical research, not patient outcomes.
A bioRxiv preprint reports that the experimental RAF inhibitor ELV-3111 suppressed MAPK signalling and tumour growth in models driven by RAF dimers, including RAS-mutant models. The researchers say that pairing it with a MEK inhibitor produced durable regressions across RAS-mutant and BRAF-mutant models, with favourable tolerability in the models studied. These are preclinical findings, not results from patients.
How binding kinetics may shape the response
RAF proteins help relay signals through the RAS–MAPK pathway, which regulates cell growth. In some cancers, mutations in RAS drive this pathway and promote RAF proteins working in pairs, or dimers. Blocking the pathway can also affect normal tissues, creating a challenge for therapies intended to inhibit tumour growth.
The authors describe ELV-3111 as a Type 1 RAF inhibitor that first binds RAF and promotes its active shape—a process they call “priming”—before rapidly dissociating. They propose that this fast off-rate helps explain the different effects in normal tissue and RAS-mutant tumours: in normal tissue, the inhibitor can prime RAF and temporarily increase MAPK activity; in tumours where RAF is already primed, the drug can suppress pathway activity and growth.
Binding kinetics describe how quickly a drug associates with and leaves its target. In this account, the time the inhibitor remains bound is central to its effects, rather than binding alone.
Combining RAF and MEK inhibition
MEK acts downstream of RAF in the MAPK pathway. The preprint reports that adding a MEK inhibitor to ELV-3111 gave complementary effects: additive pathway inhibition in tumour models and compensatory effects in normal tissues. The combination produced durable regressions in RAS-mutant and BRAF-mutant models, including a RAS-mutant model described as refractory to current therapies.
The results suggest a possible approach to balancing pathway suppression in tumours with effects in normal tissues. The work is a bioRxiv preprint, and the abstract reports model findings rather than clinical outcomes. Its competing-interest statement says several authors are employees and shareholders of Enliven Therapeutics.